|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cell sheet technology for regeneration of esophageal mucosa显示文摘The progress of tissue-engineering technology has realized development of new therapies to treat various disorders by using cultured cells. Cell-and tissue-based therapies have been successfully applied to human patients, and several tissue-engineered products have been approved by the regulatory agencies and are commercially available. In the review article, we describe our experience of development and clinical application of cell sheet-based regenerative medicine.Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been shown to be useful for removal of gastrointestinal neoplasms with less invasiveness compared with open surgery, especially in esophageal surgery. However, postoperative inflammation and stenosis are major complications observed after intensive mucosal resection. Therefore, we have developed novel regenerative medicine to prevent such complications and promote wound healing of esophageal mucosa after EMR or ESD. Transplantable oral mucosal epithelial cell sheets were fabricated from patients' own oral mucosa. Immediately after EMR or ESD, fabricated autologous cell sheets were endoscopically transplanted to the ulcer sites. We performed a preclinical study with a canine model. In human clinical settings, cell culture and cell sheet fabrication were performed in clean rooms according to good manufacturing practice guidelines, and pharmaceutical drugs were used as supplements to culture medium in place of research regents used in animal study. We believe that cell-based regenerative medicine would be useful to improve quality of life of patients after EMR or ESD. | Ryo Takagi Masayuki Yamato Nobuo Kanai Daisuke Murakami Makoto Kondo Takaaki Ishii Takeshi Ohki Hideo Namiki Masakazu Yamamoto Teruo Okano | 2012 | World Journal of Gastroenterology2012，18，37： | 9 |
| 2 | Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)显示文摘 | Masato Ozaka Yuji Matsumura Hiroshi Ishii Yasushi Omuro Takao Itoi Hisatsugu Mouri Keiji Hanada Yasutoshi Kimura Iruru Maetani Yoshinobu Okabe Masaji Tani Takaaki Ikeda Susumu Hijioka Ryouhei Watanabe Shinya Ohoka Yuki Hirose Masafumi Suyama Naoto Egawa A | 2012 | Cancer Chemotherapy and Pharmacology2012，，5： | 3 |
| 3 | A high power ultrasonic linear motor using a longitudinal and bending hybrid bolt-clamped langevin type transducer显示文摘 | YUN C H ISHII Takaaki NAKAMURA Kentaro | 2001 | Jpn J Appl Phys2001，40，： | 2 |
| 4 | CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant显示文摘 | Hiroshi Sakamoto Toshiyuki Tsukaguchi Sayuri Hiroshima Tatsushi Kodama Takamitsu Kobayashi Takaaki A. Fukami Nobuhiro Oikawa Takuo Tsukuda Nobuya Ishii Yuko Aoki | 2011 | Cancer Cell2011，，5： | 1 |
| 5 | Adjuvant treatments for resectable hepatocellular carcinoma显示文摘 | Hiroshi Ishii Junji Yamamoto Takaaki Ikari | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，5： | 1 |
| 6 | A piezoelectric linear actuator formed from a multitude of bimorphs显示文摘 | Akira Umeshima Takaaki Ishii | 2004 | Sensors and Actuaors A:Physical2004，109，3： | 1 |
| 7 | A high power ultrasonic linear motor using a longitudinal and bending hybrid bolt-clamped Langevin type transducer显示文摘 | YUN Cheol-Ho TAKAAKI Ishii KENTARO Nakamura | 2001 | Japanese Journal of Applied Physics2001，40，5： | 1 |
| 8 | Quantitative molecular diagnosis of peritoneal lavage fluid for predictionof peritoneal recurrence in gastric cancer显示文摘 | Yurika Sugita Yoshiyuki Fujiwara Hirokazu Taniguchi Takuji Mori Takaaki Ishii Hideki Niwa Yoshihiro Okada Shuji Takiguchi Takushi Yasuda Masahiko Yano Morito Monden | 2003 | International Journal of Oncology2003，，： | 1 |
| 9 | Adjuvant treatments for resectable hepatocellular carcinoma显示文摘 | Hiroshi Ishii Junji Yamamoto Takaaki Ikari | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，5： | 1 |
| 10 | Alteration of cancer stem cell‐like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck显示文摘 | Kazuaki Chikamatsu Hiroki Ishii Takaaki Murata Koichi Sakakura Masato Shino Minoru Toyoda Katsumasa Takahashi Keisuke Masuyama | 2013 | Cancer Sci2013，，11： | 1 |
| 11 | A low- wear driving method of ultrasonic motors 显示文摘 | ISHII TAKAAKI TAKAHASHI HISANORI NAKAMURA KENTARO | 2000 | IEEE Transactions on Ultrasonics Ferroelectric and Frequency Control2000，47，1： | 1 |
| 12 | Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients显示文摘AIM To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus(HCV) patients multicentricity.METHODS Interferon-ineligible/intolerant patients and non-responders to previous pegylated-interferon/ribavirin therapy with chronic HCV genotype 1b infection were enrolled. Child B, C cirrhotic patients were excluded.Patients received oral direct acting antiviral treatment consisting of 60 mg daclatasvir once daily plus 200 mg asunaprevir twice daily for 24 wk. We divided the patients into two groups of 56 elderly patients(≥ 75 years-old) and 141 non-elderly patients(< 75 years old) and compared the efficacy and safety. RESULTS Ninety-one point one percent of elderly patients and 90.1% of non-elderly patients achieved sustained virological response at 24 wk(SVR24). In the former, 1.8% experienced viral breakthrough, as compared with 3.5% in the latter(not significant). Adverse events occurred in 55.4% of the former and 56.0% of the latter. In the former, 7 cases(12.5%) were discontinued due to adverse events, and in the latter 9 cases were discontinued(6.4%, not significant). CONCLUSION Dual therapy with daclatasvir and asunaprevir achieved the same high rates of SVR24 in HCV elderly patients without more adverse events than in the non-elderly patients. | Kazuo Tarao Katsuaki Tanaka Akito Nozaki Akira Sato Toshiya Ishii Hirokazu Komatsu Takaaki Ikeda Tatsuji Komatsu Shozo Matsushima Kenji Oshige | 2017 | World Journal of Hepatology2017，9，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员